Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR 2,483.60
-17.00 (-0.68%)
At close: Oct 28, 2026
Mankind Pharma Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 153,786 | 142,776 | 122,074 | 102,604 | 87,494 | 77,816 |
Revenue Growth | 13.53% | 16.96% | 18.98% | 17.27% | 12.44% | 25.22% |
Gross Profit Gross Profit Growth | 109,273 | 100,130 | 85,399 | 69,549 | 57,463 | 52,937 |
Operating Income Operating Income Growth | 32,575 | 28,191 | 25,083 | 21,502 | 15,883 | 18,322 |
Net Income Net Income Growth | 22,426 | 19,129 | 19,910 | 19,129 | 12,819 | 14,335 |
Earnings Per Share EPS Growth | 54.24 | 46.28 | 49.19 | 47.68 | 32.00 | 35.78 |
EPS Growth | 27.25% | -5.92% | 3.16% | 49.02% | -10.57% | 13.27% |
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
India India Growth | 122,164 | 106,750 | 94,470 | 84,470 | 75,947 |
Outside India Outside India Growth | 20,613 | 15,325 | 8,135 | 2,958 | 1,868 |
Total Total Growth | 142,776 | 122,074 | 102,604 | 87,429 | 77,816 |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 26,602 | 22,077 | 24,962 | 33,865 | 15,216 | 12,793 |
Total Debt Total Debt Growth | 54,217 | 63,115 | 85,115 | 2,072 | 1,704 | 8,836 |
Net Cash (Debt) Net Cash Growth | -27,615 | -41,039 | -60,153 | 31,793 | 13,512 | 3,957 |
Net Cash Growth | - | - | - | 135.29% | 241.51% | -77.06% |
Net Cash Per Share Net Cash Per Share Growth | -66.79 | -99.29 | -148.63 | 79.25 | 33.73 | 9.88 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 33,031 | 31,213 | 24,134 | 21,524 | 18,133 | 9,198 |
Capital Expenditures CapEx Growth | -7,641 | -6,260 | -4,608 | -3,153 | -7,890 | -4,649 |
Free Cash Flow Free Cash Flow Growth | 25,390 | 24,953 | 19,526 | 18,371 | 10,243 | 4,549 |
Free Cash Flow Growth | 7.92% | 27.80% | 6.29% | 79.36% | 125.16% | -45.31% |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 71.06% | 70.13% | 69.96% | 67.78% | 65.68% | 68.03% |
Operating Margin | 21.18% | 19.74% | 20.55% | 20.96% | 18.15% | 23.55% |
Pretax Margin | 18.64% | 16.34% | 20.61% | 23.37% | 19.10% | 25.38% |
Profit Margin | 14.58% | 13.40% | 16.31% | 18.64% | 14.65% | 18.42% |
FCF Margin | 16.51% | 17.48% | 16.00% | 17.90% | 11.71% | 5.85% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 29, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 45.79 | 43.29 | 50.25 | 48.18 | - | - |
P/FCF Ratio | 40.51 | 33.18 | 51.24 | 50.17 | - | - |
PS Ratio | 6.69 | 5.80 | 8.20 | 8.98 | - | - |